Cancer research, Prenylation, Farnesyltransferase, Biochemistry and Geranylgeranyltransferase I Inhibitor are his primary areas of study. The Cancer research study combines topics in areas such as Protein kinase B and Cell growth. His study in Prenylation is interdisciplinary in nature, drawing from both 3T3 cells and Kinase.
Saïd M. Sebti has included themes like Signal transduction and Cell biology in his Farnesyltransferase study. His work in Growth inhibition and Apoptosis is related to Biochemistry. His research in Growth inhibition intersects with topics in Farnesyltranstransferase and Enzyme inhibitor.
Saïd M. Sebti focuses on Cancer research, Biochemistry, Farnesyltransferase, Prenylation and Cell biology. The concepts of his Cancer research study are interwoven with issues in Cell growth, Carcinogenesis, Signal transduction, Cell cycle and Kinase. His work deals with themes such as Endocrinology and Internal medicine, which intersect with Signal transduction.
His research integrates issues of Stereochemistry and Enzyme inhibitor in his study of Farnesyltransferase. He focuses mostly in the field of Prenylation, narrowing it down to matters related to Growth inhibition and, in some cases, STAT3. His Cell biology study integrates concerns from other disciplines, such as Malignant transformation and Molecular biology.
Saïd M. Sebti mainly investigates Cancer research, Prenylation, Cell biology, Farnesyltransferase and Molecular biology. His studies deal with areas such as Caspase 3, Pancreatic cancer, Carcinogenesis, KRAS and Kinase as well as Cancer research. The study incorporates disciplines such as Cohort study and Dose–response relationship in addition to Prenylation.
In Cell biology, Saïd M. Sebti works on issues like Malignant transformation, which are connected to SH2 domain, MMP9, Binding site and Mutant. His Farnesyltransferase research is multidisciplinary, incorporating elements of In vitro and Tumor growth. Saïd M. Sebti combines subjects such as Apoptosis, Membrane, Bcl-2 family, Cytotoxicity and Akt phosphorylation with his study of Molecular biology.
Saïd M. Sebti spends much of his time researching Cell biology, Prenylation, Protein prenylation, Geranylgeranylation and Clinical trial. His work carried out in the field of Cell biology brings together such families of science as Molecular biology, MMP9 and Binding site. He has included themes like GTPase, RALB, RALA, Ral GTP-Binding Proteins and Growth inhibition in his Prenylation study.
His research in Clinical trial intersects with topics in Protein farnesylation, Farnesyltransferase, Signal transduction, Pharmacology and Cancer therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Targeting protein prenylation for cancer therapy
Norbert Berndt;Andrew D. Hamilton;Saïd M. Sebti.
Nature Reviews Cancer (2011)
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Edwina C. Lerner;Yimin Qian;Michelle A. Blaskovich;Renae D. Fossum.
Journal of Biological Chemistry (1995)
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Jiazhi Sun;Michelle A Blaskovich;Richard Jove;Sandra K Livingston.
Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion
Jiazhi Sun;Yimin Qian;Andrew D. Hamilton;Saïd M. Sebti.
Cancer Research (1995)
Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor
Edwina C. Lerner;Yimin Qian;Andrew D. Hamilton;Saïd M. Sebti.
Journal of Biological Chemistry (1995)
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice.
Zhi Chen;Jiazhi Sun;Anne Pradines;Gilles Favre.
Journal of Biological Chemistry (2000)
Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Edwina C. Lerner;Ting Ting Zhang;David B. Knowles;Yimin Qian.
The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent Manner *
Andreas Vogt;Jiazhi Sun;Yimin Qian;Andrew D. Hamilton.
Journal of Biological Chemistry (1997)
Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis
Kun Jiang;Jiazhi Sun;Jin Cheng;Julie Y. Djeu.
Molecular and Cellular Biology (2004)
Inhibitors of protein isoprenyl transferases
David J. Augeri;Kenneth J. Barr;Bernard G. Donner;Stephen A. Fakhhoury.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: